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Abstract
Mitochondrial myopathy, associated with muscle weakness and progressive external
ophthalmoplegia, is caused by mutations in mitochondria oxidative phosphorylation genes including
the heart–muscle isoform of the mitochondrial adenine nucleotide translocator (ANT1). To develop
therapies for mitochondrial disease, we have prepared a recombinant adeno-associated viral vector
(rAAV) carrying the mouse Ant1 cDNA. This vector has been used to transduce muscle cells and
muscle from Ant1 mutant mice, which manifest mitochondrial myopathy. AAV-ANT1 transduction
resulted in long-term, stable expression of the Ant1 transgene in muscle precursor cells as well as
differentiated muscle fibers. The transgene ANT1 protein was targeted to the mitochondrion, was
inserted into the mitochondrial inner membrane, formed a functional ADP/ATP carrier, increased
the mitochondrial export of ATP and reversed the histopathological changes associated with the
mitochondrial myopathy. Thus, AAV transduction has the potential of providing symptomatic relief
for the ophthalmoplegia and ptosis resulting from paralysis of the extraocular eye muscles cause by
mutations in the Ant1 gene.
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Introduction
Mitochondrial myopathy, generally defined as progressive muscle weakness associated with
ragged red fiber muscle fibers (RRF)1 and the proliferation of subsarcolemmal mitochondria,
can be caused by an assortment of defects in mitochondrial oxidative phosphorylation
(OXPHOS) genes.2 Severe cases of mitochondrial myopathy can present with progressive
external ophthalmoplegia (PEO), caused by paralysis of the extraocular eye muscles.3 One of
the best characterized causes of mitochondrial PEO is mutations in the nuclear DNA (nDNA)-
encoded gene for the heart–muscle isoform of the adenine nucleotide translocator (Ant1) gene.
4
The ANTs export ATP generated by OXPHOS out across the mitochondrial inner membrane
in exchange for cytosolic ADP, and thus are the main modulators of energy flux in the aerobic
cell. ANT is an integral mitochondrial inner membrane protein that forms functional
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homodimers or -tetramers.5 ANTs work as electrogenic pumps6 and account for about 10%
of mitochondrial inner membrane protein in tissues with high ATP requirements such as the
heart and muscle. Efficient export of ATP also plays an important role in tissue development
and the ANTs are thought to participate in the regulation of the mitochondrial permeability
transition pore (mtPTP), and thus to play an important role in apoptosis.7 Humans have three
different ANT isoform genes while mice have only two. However, the heart/muscle-specific
isoform (ANT1) is common to both species.8
A mouse model of mitochondrial myopathy with RRFs was created by the genetic inactivation
of the Ant1 gene. This recessive mutant results in a massive proliferation of muscle
mitochondria and the hyperinduction of mitochondrial enzymes along with increased
mitochondrial DNA (mtDNA) rearrangements.9 Hence, the ANT1-deficient mouse provides
an excellent model for exploring therapeutic approaches for mitochondrial myopathy.
While there is a growing awareness of the importance of myopathy in the morbidity of disease,
few therapeutic options are currently available to ameliorate the attendant muscle symptoms.
Myoblast injection10 and direct DNA transformation11 have been explored, but met with only
modest success. By contrast, virus-mediated gene transduction, particularly using adeno-
associated viral (AAV) vectors12 has proven more successful. The non-pathogenic AAV has
a relatively high affinity for muscle13 and can efficiently infect both dividing and nondividing
muscle cells. Infection with recombinant AAV (rAAV) virus results in both a persistent
episomal form as well as integration into the host genome.14 Hence, the AAV system has
permitted long-term expression of transgenes, thus enhancing its attractiveness for treating
muscle disorders.
Although most muscles are affected in mitochondrial myopathy, the primary concern of these
patients is weakness of the extraocular eye muscles resulting in ophthaloplegia and ptosis.
Since the extraocular eye muscles are small, very few muscle cells may need to be treated to
provide significant symptomatic relief.
The rAAV system has already been successfully used to transduce mitochondrial-targeted
transgenes. The mtDNA ATP6 gene with a corrected genetic code was allotypically expressed
from the nucleus and the ATP6 polypeptide successfully imported into the mitochondria by
coupling it to a mitochondrial targeting peptide.15 Furthermore, the yeast NADH:Coenzyme
Q10 oxidoreductase gene has been transduced into the cells of a Leigh syndrome patient with
nDNA-encoded complex I-deficiency.16 While these studies are unlikely to have immediate
therapeutic applications, they demonstrate that the rAAV system can be used to transduce small
OXPHOS polypeptides into human cells. Hence, the AAV system should be ideal for
transduction of the 300 amino-acid Ant1 gene, thus permitting treatment of the mitochondrial
myopathy and PEO resulting from mutations in the Ant1 gene.
In the present study, we report preparation of an rAAV harboring the mouse Ant1 cDNA and
the use of this virus to transduce the nuclei of skeletal muscle fibers in ANT1-deficient mice.
This resulted in the successful introduction of functional ANT1 protein into the skeletal muscle
mitochondria and the amelioration of the biochemical and histopathological effects of the
Ant1 genetic defect.
Results
Creation and production of the Ant1 transgene vector
The 1.2 kb Ant1 cDNA was introduced into the AAV 2 vector pTR-UF117 by substituting the
GFP gene, transcribed from the CMV promoter, with the mouse Ant1 cDNA. The resulting
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pAAV-ANT1 vector was sequence verified and viral vector stocks were produced and purified
to yield multiplicities of infection (MOI) of 9 × 1012 per cell.
Transduction of Ant1 into cultured myoblasts and myotubes: expression and cytotoxicity
Primary myoblastoid cell lines were prepared from 1-month-old Ant1+/+ (wild-type) and Ant1
−/− (ANT1-deficient) mice. The undifferentiated myoblasts were transduced with AAV-ANT1
and AAV-GFP vectors and the transduction efficiency, the intracellular fate of the ANT1
transgene protein and the cell survival were monitored using the AAV-GFP as an internal
control. Cell lines overexpressing ANT1 were then evaluated for expression of the ANT1 cDNA
before and after differentiation of the myoblasts into myotubes. Parallel experiments were
conducted using the immortalized myoblast cell line C2C12 (ATCC® No. CRL-1772).
The rAAV-GFP transduction efficiency for cultured mature myotubes, derived from ANT1-
deficient mice, was evaluated by GFP expression and was found to be 10–15% lower than
transduction of myotubes from wild-type tissue, perhaps due to problems with viral
internalization in ANT1-deficient cells. On the other, hand, Ant1+/+ and −/− myoblasts showed
no significant differences in transduction efficiency. Consequently, we routinely transduced
cultured myoblasts and then induced them to differentiate into myotubes for further
investigation.
Primary myoblastoid cell lines generated from ANT1-deficient and wild-type mice were
analyzed for cell growth rate by measuring their increase in cell number after 3 days of growth
with or without AAV-ANT1 transduction (Figure 1). Myoblasts lacking ANT1 increased in
cell number about ⅓ as fast as wild-type myoblasts, indicating the importance of ANT for
myoblast physiology. AAV-ANT1 transduction did not significantly inhibit cell proliferation
of either the Ant1+/+ or −/− myoblasts after 3 days in culture. However, transduction of the
ANT1-deficient myoblasts with AAV-ANT1 did not restore normal growth rate either.
Therefore, increased ANT1 transduction did not negatively affect the growth of cells with
ANT1, but did not stimulate the growth of cells without ANT1 (Figure 1).
The persistence of the AAV-ANT1 vector in transduced primary cultured myoblasts was
monitored by PCR. Vector-specific sequence amplicons as well as ANT1 transcripts (detected
by reverse transcription PCR (RT-PCR)) were detectable at 1 week postinfection in myoblasts
and at 2 weeks postinfection in the myotubes, demonstrating that the transgenic vector can be
retained over an extended period of time.
Myoblasts express both ANT1 and ANT2 isoforms, whereas differentiated myotubes or adult
muscle (1 month of age) expresses only ANT1.18
By using isoform-specific antibodies, we detected the ANT1 protein by Western blots in the
AAV-ANT1-transduced ANT1-deficient myoblasts and throughout their differentiation
process into myotubes (Figure 2a). Thus, the AAV-ANT1 vector is able to transduce the
Ant1 cDNA into ANT1-deficient cells and result in the expression of ANT1 mRNA and protein
in both myoblasts and myotubes, with minimal effect on the viability of the muscle cells.
Mitochondrial localization of the ANT1 transgene protein—To determine if the
ANT1 transgene protein was properly integrated into the mitochondrial inner membrane,
mitochondria were purified by density gradient from ANT1-deficient myoblasts 14 days after
transduction with AAV-ANT1. The transgene ANT1 protein, detected by Western blots using
ANT1-specific antibody, colocalized with the mitochondrial inner membrane protein
cytochrome c oxidase subunit IV (COXIV) (Figure 2b). Subfractionation of the AAV-ANT1-
transduced Ant1−/− mitochondria into mitochondrial membrane and matrix fractions
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confirmed that the transduced ANT1 protein was inserted into the mitochondrial inner
membrane (Figure 2b, insert).
The mitochondrial localization of the ANT1 protein was further confirmed by staining AAV-
ANT1-transduced ANT1-deficient myotubes with a general ANT antibody. The ANT1
immunofluorescence colocalized with a mitochondria-specific counterstain (Figure 2c).
Therefore, the ANT1 transgene is expressed in both myoblasts and myotubes and the transgene
protein is specifically targeted to the mitochondrial inner membrane.
AAV-ANT1 transduction of mouse muscle
The AVV-ANT1 vector was next used to transduce ANT1 activity into the skeletal muscle of
ANT1-deficient mice. AAV-ANT1 vector was injected into the gastrocnemius muscles in the
left hind limb of ANT1-deficient newborn mice, the right leg serving as a control. The animals
were killed at different times and the muscles assessed for AAV-ANT1 gene content and
ANT1 transgene expression. The AAV-ANT1 viral DNA was found to be primarily limited to
the injected muscle groups, although a weak signal was also found in the liver, suggesting
minor systemic distribution of the viral vector through the bloodstream (Figure 2d).
Detection of the Ant1 transcript by RT-PCR revealed strong expression in the left injected hind
limb. This expression was roughly proportional to the amount of vector injected (Figure 2e).
The ANT1 protein expression in injected skeletal muscle was also assessed by Western blot,
and found to correspond with the ANT1 transcript levels. The injected left gastrocnemius
muscle was found to be positive for ANT1, while other muscle groups were uniformly negative
(Figure 2f).
Transgene distribution in mouse muscle—ANT1 protein expression was also observed
by immunohistochemistry in the transduced left hind limb muscle tissue. A general ANT
antibody was used here, since ANT2 expression is very low in muscle and confined to
endothelial and connective tissue and mononuclear cells.
In adult Ant1−/− mice, the ANT1 transgene protein was observed in the immediate vicinity of
the injected muscle, as confirmed by coinjecting the AAV-ANT1 virus with the AAV-GFP
vector and by tissue damage caused by the oversized needle used. This is consistent with
previous studies, which have shown that the AAV vector can only penetrate five to 10 fiber
layers in adult muscle tissue.18 The expression of the transgenic ANT1 protein in individual
fibers of adult mice gave a particulate staining pattern similar to that obtained for ANT1 in
wild-type muscle (Figure 3a), confirming that transgenic ANT1 protein was correctly targeted
to the mitochondrion.
Injection of AAV-ANT1 virus into neonatal ANT1-deficient muscle resulted in transgene
expression in a much greater number of muscle fibers (Figure 3b). This may reflect the broader
distribution of the vector upon injection into neonatal tissue as well as the initial infection of
not only muscle fibers but also a larger number of muscle precursor cells present in neonatal
tissue.19 These transduced precursor cells could subsequently proliferate and differentiate into
mature fibers expressing the transgene.
Comparison of the immunohistological staining for ANT1 in 1- and 3-month-old animals
versus 1-year-old animals revealed a continued expression of the Ant1 transgene, even though
the level of expression declined somewhat with age (Figure 3c).
ANT1 activity in AAV-ANT1-transduced muscle—To assess the functionality of the
transgenic ANT1 protein within the mitochondrial inner membrane, we assessed the ATP-
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binding and ATP-transport capacities in the AAV-ANT1-transduced tissues. First, we
examined the level of ANT protein in tissue homogenates of AAV-ANT1-transduced
gastrocnemius muscle using the fluorescent ATP analogue naphthoyl-atractyloside (N-ATR),
which bind to the ATP binding site of the ANTs. Changes in N-ATR fluorescence by
displacement with the irreversible inhibitor C-ATR permitted quantification of the number of
ANT molecules.
AAV-ANT1 transduction of the left gastrocnemius muscle of ANT1-deficient mice increased
the level of ANT1 protein from undetectable to 5–30% of wild-type ANT1 levels (Figure 4a).
Injection of wild-type muscle with AAV-ANT1 vector did not significantly increase ANT1
binding capacity. Hence, AAV-ANT1 transduction partially restored N-ATR binding capacity,
and thus was able to generate functional ANT1 protein in the previously ANT1-deficient
muscle mitochondria. Moreover, addition of the transgenic Ant1 did not adversely alter the
maximum level of ANT1 protein in wild-type muscle, suggesting that chromosomal Ant1
expression may be regulated.
To confirm that the transgene ANT1 molecules were able to transport ATP, we measured the
rate of ATP export from coupled, respiring mitochondria isolated from 1-year-old ANT1-
deficient mice, transduced with AAV-ANT1 as neonates. Mitochondria from AAV-ANT1-
transduced muscle secreted up to 45% of the ATP produced from wild-type mitochondria in
multiple assays from two independent mice (Figure 4b). This indicates that the N-ATR binding
activity in transduced tissues was in fact functional ANT1.
Interestingly, mitochondria from the ANT1-deficient mouse muscle secreted about 5–10% of
the ATP secreted by wild-type muscle mitochondria. This residual ATP secretion could be due
to the leakage of ATP through damaged mitochondrial membranes. Alternatively, it could be
due to the presence of a small portion of mitochondria from nonmuscle cells, which
contaminated the muscle of the ANT1-deficient hind limb. These mitochondria would still
express ANT2, and hence would secrete ATP. This later alternative seems the more probable
since addition of the irreversible ATP-inhibitor C-ATR reduced ATP secretion to <2% in both
Ant1−/− and Ant1+/+ mitochondria.
Whatever permitted the secretion of some ATP from the ANT1-deficient mitochondrial
preparations, the amount of ATP secreted by the AAV-ANT1-transduced hind limb muscle
mitochondria was much greater than that of the untransduced mitochondria. This confirms that
AAV-ANT1 transduction was able to reconstitute mitochondrial ATP secretion in the ANT1-
deficient mouse skeletal muscle.
Histopathological analysis of AAV-ANT1-transduced ANT1-deficient muscle—
AAV-ANT1 transduction of the muscles of ANT1-deficient mice also significantly
ameliorated the pathological features of mitochondrial myopathy. In wild-type mice, the soleus
is composed predominantly of slow-twitch, oxidative, Type I fibers, whereas the gastrocnemius
is predominantly fast-twitch, glycolytic, Type IIa/b fibers.20 In the ANT1-deficient mice, these
muscle groups exhibited the classical features of mitochondrial myopathy including altered
fiber size and number, central nuclei, altered fiber type characteristics and RRFs.21 In addition,
the majority of the Type II and IIa fibers in the ANT1-deficient gastrocnemius muscle take on
a histological appearance more similar to the oxidative, Type I fibers, as determined by ATPase
activity and increased levels of the mitochondrial enzymes NADH-dehydrogenase (NADH-
DH), succinate dehydrogenase (SDH) and cytochrome oxidase (COX). Still, the size of these
muscle fibers and the MHC expression pattern remain unchanged.
In the AAV-ANT1-transduced muscle, some muscle tissue damage was observed at the
injection site, possibly resulting from endomysial infiltration of mononucleic cells resulting in
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the formation of connective scar tissue. However, these same effects were observed following
injection of the AAV-GFP vector, and thus were not a consequence of Ant1 cDNA expression.
In both adult and newborn ANT1-deficient muscle, the acute tissue injury observed following
AAV-ANT1 injection resolved in about 2 weeks (Figure 5a1 and a2).
By contrast, transduction of ANT1-deficient muscle with the AAV-ANT1 vector resulted in
significant reductions in the histopathological features associated with mitochondrial
myopathy, which were not seen in muscle injected with the control vector. The most dramatic
therapeutic effect of ANT1-AAV transduction was the reduction in RRFs in the soleus and/or
gastrocnemius Type I muscle fibers of ANT1-deficient mice (Figure 5b). However, reversal
of the RRF pathological was not complete since some evidence of subsarcolemmal red staining
was retained.
Following AAV-ANT1 transduction, the rounded pathologic aspect of the muscle fibers of the
ANT1-deficient muscle were restored to the more angular structure of normal fibers. Moreover,
the number of fibers with central nuclei was clearly reduced in the AAV-ANT1-injected areas
of the gastrocnemius. Finally, the endomysial inflammation pattern visible in the highly
oxidative fibers of the soleus muscle of Ant1−/− mice was reduced in the treated muscles
(Figure 5c).
In addition to the reduction in RRFs, AAV-ANT1 transduction of the ANT1-deficient
gastrocnemius muscle resulted in a striking reduction in the levels of the OXPHOS enzymes
NADH-DH, SDH and COX, with the histochemical staining approaching normal levels (Figure
5d). However, AAV-ANT1 transduction had no apparent influence on myofiber size or MHC
expression pattern (data not shown).22 Therefore, transduction of Ant1 into ANT1-deficient
muscle dramatically improved the muscle pathology associated with this ANT1 enzyme defect.
Discussion
We have successfully treated the mitochondrial myopathy of the ANT1-deficient mouse
through AAV-assisted gene transfer of the Ant1 cDNA. The Ant1 cDNA was transcribed from
a CMV promoter, and transduced myoblasts and myotubes synthesized the Ant1 mRNA and
protein.
Following an initial phase, when the ANT1 protein levels were highest, the level of ANT1
expression achieved a relatively constant level in both cultured myoblasts and in differentiated
myotubes. The initial higher level of ANT1 expression was most likely the product of the
transient presence of episomal copies of the rAAV-ANT1 vector.
As expected, developing and regenerating muscle tissue showed higher transduction
efficiencies than differentiated myofibers.23 The slightly reduced transduction levels of
ANT1-deficient myotubes might be the result of changes in the efficiency of receptor-mediated
endocytosis or due to other ATP requiring processes necessary for efficient AAV transduction.
24
An initial concern was that viral transduction with the Ant1 gene would result in excessively
high expression levels of ANT1 and that this would induce apoptosis. The ANTs interact with
the mtPTP and are known to regulate its activation by Ca2+ and ANT ligands leading to
apoptosis.25 Reduction of ANT1 activity in either the mutant mice or in ANT1-mutant PEO
patients has not been observed to increase apoptosis,26 whereas ANT1 expression due to
Ant1 cDNA transfection into nonmyogenic cultured cells has been reported to induce apoptosis.
27 However, our data suggest that increased apoptosis may not be a concern during the
transduction of skeletal muscle with the Ant1 cDNA. This is because myoblasts, myotubes,
skeletal muscle and heart all naturally express high levels of ANT1 and thus must be resistant
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to any proapoptotic effects that this protein might have. Other cell types, which generally
express only ANT2, could well be induced to undergo apoptosis as a consequence of the
nonphysiological expression of ANT1. Therefore, we feel that it should be possible to transduce
the Ant1 cDNA into autosomal-dominant PEO patients harboring Ant1 missense mutations in
sufficiently high levels to ameliorate symptoms without also inducing muscle cell necrosis and
apoptosis.
While in vivo, injection of the AAV-ANT into the muscles of Ant1−/− mice resulted in a 5–
30% increase in ANT1 protein and a restitution of between 25 and 45% of the normal ATP
secretion levels, AAV-ANT1 transduction of Ant1−/− myoblasts did not restore the normal
growth rate. Since myoblasts express both ANT1 and ANT2, the reduced growth rate of the
Ant1−/− myoblasts may not be entirely related to deficiency in ATP export. Perhaps other
physiological factors may be limiting growth rate, such as nucleotide pools28 or signal
transduction pathways,29 which require constant higher levels of ANT1.
Irrespective of the inability of AAV-ANT1 transduction to restore normal myoblast growth
rate, it substantially increased the level of ANT1 protein and ATP export in the skeletal muscle
of the ANT1-deficient mice. Moreover, AAV-ANT1 transduction resulted in the amelioration
of many of the histopathological abnormalities associated with mitochondrial myopathy,
including reduction of the number of RRFs and suppression of the hyperinduction of the
OXPHOS enzymes, NADH-DH, SDH and COX. Hence, these results demonstrate that
mitochondrial myopathy can be locally treated by AAV-mediated transduction of the Ant1
gene.
Having achieved this success, there are several ways that this procedure could be improved.
Transgene expression might be enhanced by employing other promoters such as the
endogenous Ant1 promoter or the muscle mitochondrial creatine phosphokinase promoter.
Muscle infectivity could be improved by changing the AAV vector capsid genes to serotypes
with higher muscle affinity.30,31 Viral replication and thus transduction efficiency could be
enhanced by using dimeric or self-complementary AAV vectors.32
One potential difficulty with using the current AAV-ANT1 system for treating human
mitochondrial myopathy resulting from Ant1 mutations is that the human disease is inherited
as a dominant, rather than a recessive as in the current mouse model. The most likely reason
for this difference is that the mouse mutant is a null, while the reported human mutants are
missense mutations. Since the ANTs are thought to function as homo-oligomeric proteins, one
defective subunit could inactive an entire complex, thus acting as a dominant negative. If this
is the case, then high-level expression of a functional transgene may be required to generate
enough subunits to assure sufficient functional enzyme to ameliorate the symptoms of
autosomal PEO in patients.
In conclusion, using the Ant1 knockout mouse as a model system, we have demonstrated that
AAV transduction provides a robust method for reconstituting OXPHOS activity in muscle
mitochondria. By introducing a functional copy of Ant1 into one of the most prominently
affected tissues in this mouse model, we were able to increase Ant1 expression to a level that
resulted in the amelioration of the biochemical deficiencies and histopathological features.
Thus, AAV-mediated gene therapy may have real potential for treatment of the
ophthalmoplegia in autosomal PEO.
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Vector construction and amplification
The mouse Ant1 cDNA (AF240002)8 cloned in pBlue-script SK+ (Stratagene) and AAV vector
plasmids were propagated in Escherichia coli SURE®2 cells (Stratagene) and the plasmids
purified using commercial kits (QIA-prep, Qiagen). The 1.2 kb Ant1 cDNA fragment was
cloned into the AAV vector pTR-UF1,33 creating the vector pAAV-ANT1. Insert size was
confirmed by XhoI digest (New England Biolabs). Orientation of the insert and integrity of
cloning sites was sequence verified with primers located in the CMV promoter (cANT1-SDSA:
AGG CCT GTA CGG AAG TGT TA) and polyA region (SV40polyA: CCC CTG AAC CTG
AAA CAT AA). AAV-ANT1 vector stocks were produced by two-plasmid cotransfection and
double CsCl purification.17
In vitro transfection and transduction
Primary myoblasts derived from 3-day-old S4/129 (wild-type) and W1/129 (ANT1-deficient)
mouse gastrocnemius muscle were purified to >99%.34 Myoblasts grown in GM medium
(Ham’s F10 (Gibco), 20% FBS (Hyclone), 5 ng/ml bFGF (Promega)/5% CO2/37°C) on dishes
coated with E–C–L matrix (Upstate Biotech) were plated in 24-well tissue culture plates and
plating efficiency was controlled to avoid significant variation among groups. At 48 h after
plating, cells were transduced with the viral vectors, either with AAV-ANT1 plus pTR-UF1
at a 1:1 ratio or with AAV-ANT1 alone. To determine optimal titers for transduction of
myocytes, AAV-ANT1 virus was administered at MOIs of 1 × 108, 1 × 1010 and 1 × 1012.
Differentiation of myoblasts into myotubes was induced by substituting FBS with horse serum.
Growth rates were estimated by determining the cell number 3 days after transduction/
differentiation for cell viability by trypan blue exclusion. Assessment of transgene expression
was carried out on clonal cultures of transduced myoblasts before and after differentiation.
Quantitative analysis for morphological changes was carried out using light and fluorescent
microscopy and by staining with Hoechst-33258 (Sigma).
In vivo expression of AAV-ANT1 from murine skeletal muscle
All animal experiments were approved by the Emory University and UCI IACUC committees.
One group of S4/129 controls and W1/129 (ANT1−/−) mice were injected with 1:1 AAV-
ANT1 and AAV-GFP to optimize the injection strategy. A second group was injected with
phosphate-buffered saline (PBS) in the right hind limb and with the AAV-ANT1 transgene
vector in the left hind limb (contralateral leg).
Adult mice were given standard intramuscular injections.35 Neonatal mice were collected at
3 days of age and anesthetized by hypothermia.36 A short longitudinal skin incision was made
on the back lower hind limb and with the aid of a dissecting microscope a 33-gauge hypodermic
needle (Hamilton; Reno, NV, USA) was inserted into the posterior group of muscles
(gastrocnemius, soleus) parallel to the fiber orientation and 2 μl were injected in three separate
longitudinal injections (a total of 6 μl and 1 × 109 infectious units in PBS/10% glycerol). The
incision was closed with tissue adhesive (Vectabond™). At 2, 7, 14, 30 and 90 days as well as
1 year after injection, the animals were killed by cervical dislocation and tissues were collected
for analysis.
Isolation and purification of mitochondria—Skeletal muscle mitochondria were
isolated by tissue disruption, differential centrifugation and Iodixanol-gradient
centrifugation37 (OptiPrep™, Invitrogen/AXIS-SHIELD) using a self-generating continuous
gradient.38 Respiration of mitochondria was assessed in a Clark-type O2 electrode39
(Hansatech). Mitochondria from cultured cells were prepared using hypoosmotic swelling40
and Iodixanol density-gradient centrifugation. Purified mitochondria were subfractionated into
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outer membrane, inner membrane and matrix using digitonin (Roche) and differential
centrifugation.41
DNA and RNA analysis—The Ant1 genotype of animals was determined by differential
PCR.9 Nucleic acids were isolated from soleus and gastrocnemius muscle using Trizol® (Life
Technologies), and RNA, DNA and protein were collected taking into account the small
samples available (1 × 106 myocytes, 250 mg of muscle tissue). RNA expression of AAV-
ANT1 was assayed by semi-quantitative RT-PCR (Roche). Purified RNA was reverse
transcribed using a vector-specific primer (ANT1: SV40polyAR: TTC ACT GCA TTC TAG
TTG AGG A). cDNA was synthesized using nested oligonucleotides (cANT1-SDSA: see
above; ANT-1-E1R: AGC AGC AGT TTG ACC CTC TC).
Western blot analysis—Western blots were developed by using affinity-purified
polyclonal antibodies.9 The protein content of cell and tissue lysates was determined by Lowry
protein assay (Pierce). Protein (25 μg) of total tissue lysate or 15 μg of isolated mitochondrial
lysate were separated using 10% TG-SDS–PAGE in an MES-buffer system (NOVEX/
Invitrogen), blotted onto nitro-cellulose membranes (Biorad) and the blots stained with
Ponceau S (Sigma). Blots were reacted with 2 μg/ml ANT1, 4 μg/ml ANT2, COX IV
(Molecular Probes) and Hsp70 (Stressgen) antibodies. Bound antibody was detected by a
peroxidase-conjugated secondary antibody (Sigma) and signals were visualized by
chemiluminescence substrate (ECL, Amersham/Pharmacia).
Assays for ANT1 function
Functional ANT1 protein in the muscle homogenates was assessed with fluorescent N-ATR.
42 Mitochondrial protein (100 μg) were assayed in 300 μl reaction mix in a temperature-
controlled (25°C) stirred quartz cuvette on a LS50B fluorescence spectrometer (Perkin-Elmer).
The mitochondria were reacted with N-ATR, the N-ATR competed off the ANT with C-ATR
(Calbiochem) and the increased fluorescence monitored by fluorimetry.43 N-ATR binding was
quantified as nmol C-ATR/mg mitochondrial protein, normalized to citrate synthase (CS)
activity.44
The mitochondrial export of ATP by the ANT carrier too was assayed using a kinetic
bioluminescence assay45 (ATP Bioluminescence Kit CLS II, Roche). Coupled mitochondrial
protein (25 μg) were combined with 25 μl of bioluminescent reagent in a 200 μl reaction in a
Sirius-Luminometer (Berthold Detection Systems). Pyruvate and malate were used as
respiration substrate, the reaction started by adding ADP, and the ATP secreted into the reaction
buffered quantified every 15 s for 10 min in duplicate (40 readings). ATP production and ATP
export were inhibited with C-ATR and Oligomycin (Sigma), respectively. Bioluminescence
ATP determinations were correlated with ATP standards and expressed as nM ATP/min/mg
mitochondrial protein and normalized to CS activity.
Pathophysiological assessment—The posterior muscles of the lower hind limb from
injected mice and controls were removed at day 7, 14, 28 and 96 after viral transduction. After
removal of tendons, blood vessels and connective tissue, muscles were weighted and then either
frozen or fixed with formalin.
Immunohistochemistry
Myocytes cultured on chamber slides (Tissue-Tek) and stained with 250 ng/ml Mitotracker
CMX-ROS (Molecular Probes) were fixed with ice-cold acetone/methanol (3/1) and
permeabilized with 0.1% Triton X-100 (Calbiochem). After blocking with 2% serum in PBS/
1% BSA, cells were incubated with 2 μg/ml ANT-specific antibody (Santa Cruz Biotech.) in
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PBS/0.05% Triton X-100 and the bound antibody detected by an Alexa-Fluor 488-conjugated
secondary antibody (Molecular Probes).
Snap-frozen tissues were embedded in OCT compound #4583 (Tissue-Tek/VWR). Serial
cryosections (10 μm thick) from the midbelly of the muscle were transferred on
Vectabond™-treated glass slides, air-dried (20–30 min at RT) and washed 2 × in PBS/0.1%
Tween-20, blocked in 10% normal serum in PBS/1% BSA and incubated with the ANT-
specific antibody (4 μg/ml). Endogenous peroxidase was quenched with 0.3% H2O2 in PBS
for 5 min. After 30 min, the secondary biotinylated antibody (Vector Laboratories) was applied
for 30 min and detected by a biotinylated horseradish peroxidase conjugate (Vectastain Elite
ABC Kit). After DAB-substrate solution color development, sections were dehydrated, cleared
and mounted (Histo-Clear™, Histomount™, Nat. Diagnostics).
Histochemistry
Transverse sections from gastrocnemius muscles were analyzed by H&E and Gomori Tri-
Chrome staining46 and also stained for NADH-DH, SDH and COX.47
Images were acquired using a CCD camera (SPOT-Camera/Software) mounted on an Axioplan
2 (Carl Zeiss) and 10 different sections, defined by their position relative to the poplieatal
artery, were analyzed using image processing software (Adobe® Photoshop 7) and the results
averaged.
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Growth rates of primary myoblast cultures from wild-type and ANT1-deficient muscle, with
and without AAV-ANT1 transduction. Myoblasts were generated from wild-type (C) and
ANT1−/− (ANT) mice, and either left untransduced (solid bars) or were transduced with
rAAV-ANT1 (AAV-ANT1, hatched bars). Cell numbers were counted at day 0 (0) and day 3
(3) after plating.
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ANT1 expression in pAAV-ANT1-transduced myoblasts, myotubes and skeletal muscle. (a)
Detection of ANT1 protein in myoblasts and myotubes. Western blot analysis of ANT1 in
wild-type (WT) and ANT1−/− (ANT1-) myoblasts 5 days after transduction with AAV-ANT1
(tWTb, tANT1-b) and in myotubes 7 days after induction of differentiation (tWTd, tANT1-d),
probed with ANT1 and COXIV-specific antibodies. (b) Mitochondrial localization of ANT1
transgenic protein in myoblasts. Western blot analysis of subcellular fractions obtained from
wild-type (WT), untransduced ANT1−/− (ANT1-) and AAV-ANT1-transduced ANT1−/−
(tANT1-) myoblastoid cell lines. Whole-cell lysates (LYS), cytoplasmic fractions (CYT) and
mitochondrial fractions (MIT) were probed with antibodies specific for Hsp70, ANT1 and
COX IV. The inset shows the localization of ANT1 in tANT- mitochondria in the mitochondrial
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lysate (MLYS) and inner (IM), but not the outer mitochondrial membrane (OM) or the
mitochondrial matrix (M). (c) Immunofluorescence microscopy of myocytes: Wild-type (WT),
ANT1−/− (ANT1-) and ANT1−/− myocytes transduced with AAV-ANT1 (tANT1-) were
stained with an antibody specific for ANT (green fluorescence). Mitochondria were
counterstained with Mitotracker CMX-ROS (red fluorescence). (d) Detection of rAAV-ANT1
DNA in transduced skeletal muscle. Agarose gel electrophoresis of PCR- fragments obtained
from left (L) and right (R) gastrocnemius muscle and liver (I) of 1-month-old mice. DNA was
extracted and amplified with oligonucleotides specific for the transgene Ant1 cDNA. MW: 50
bp ladder; C: control; P: pAAV =AAV vector; WT =wild-type control; tWT and tANT1- =wild-
type and ANT1−/− tissues injected with the transgene. (e): Detection of transgenic Ant1
mRNA. Agarose gel electrophoresis of transgene-specific RT-PCR fragments (cANT), from
untransduced WT and tissues transduced with either the full viral dose (tANT1-) and half-dose
(tANT1-1/2). Utilization of comparable levels of RNA was confirmed by RT-PCR
coamplification of the GADPH mRNA. Abbreviations as in (d), except P− =AAV vector
without transgene, P+ =AAV containing the Ant1 transgene. (f) Detection of ANT1 protein in
skeletal muscle. Western blot analysis of ANT1 in mouse tissues 4 weeks after injection, probed
with ANT1 and COXIV-specific antibodies. WT/G =control gastrocnemius muscle; tANT1-
=ANT1-deficient mice injected with rAAV-ANT1 in the lower left hind limb; tANT1-/V
=vastus lateralis, tANT1-/S =semitendinosus muscle, tANT1-/T =tibialis, tANT1-/G
=gastrocnemius muscle. MW =31 kDa molecular weight marker.
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Ant1 expression in gastrocnemius muscle detected by immunohistochemical stain (DAB) for
ANT. (a) Transgene Ant1 expression in wild-type (tWT) and ANT1−/− (tANT1-) mice injected
with the transgene at 3 months of age. (b) Ant1 expression in a 1-month-old ANT1−/− mice
injected with rAAV-ANT1 as a neonate (center), showing transduction of upper right quadrant
of the section (bar scale: 20 μm). Flanking pictures show untransduced (−) (left) and transduced
(+) (right) areas of the muscle (bar scale: 50 μm). (c) Ant1 expression in a 1-year-old wild-
type (WT) and ANT1−/− mouse (ANT) injected with rAAV-ANT1 (tANT1-) as a neonate (bar
scale: 20 μm).
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Demonstration of active ANT1 in transduced skeletal muscle. (a) Quantification of transgenic
ANT1 protein by binding of the ATP analogue N-ATR in mitochondrial preparations from 3-
month-old mouse right (RL) and left (LL) hind limb muscles. Neonates were injected with
either saline (WT-, ANT-) or rAAV-ANT1 (tWT-, tANT1-). ATP binding capacities were
quantified by the increase in N-ATR fluorescence following competitive release with C-ATR,
normalized to CS activities. Six animals were tested per group. *P≤0.01. (b) ATP excreted
from transduced skeletal muscle mitochondria. Mitochondria were isolated from 1-year-old
mouse hind limb muscles, injected with saline (ANT-RL) or with rAAV-ANT1 (tANT-LL) as
neonates. ATP production per mg mitochondrial protein was measured in triplicate and
normalized to CS activity. ATP export in wild-type (WT) and ANT1−/− mitochondria (ANT),
could be blocked with CATR (WT-0, ANT-0). Six animals tested per group. Two ANT1−/−
mice (1 and 2) were transduced with rAAV-ANT1 as neonates, the left hind limb treated with
virus (LL) and the right hind limb treated with saline vehicle (RL). Mitochondria from each
limb were isolated and analyzed for ATP secretion. *P≤0.005.
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Reversal of mitochondrial myopathy following rAAV-ANT1 transduction of adult ANT1-
deficient mouse muscle. (a) Frozen sections of gastrocnemius muscles stained with modified
Gomori-Trichrome (a1) or H&E (a2) 2 weeks after transverse injection of 3-month-old wild-
type (WT) and ANT1−/− (ANT1-) mice with an 18-gauge needle. (b) Gomori-Trichrome-
stained frozen sections of soleus muscles from 1-month-old wild-type (WT), ANT1−/−
(ANT1-) mice, ANT1−/− mice transduced with rAAV-ANT1 as neonates. Insets show lower
magnification of muscle area (bar scales: 20 μm; insets: 50 μm). (c) H&E staining of
gastrocnemius muscles from the same animals. Solid arrows indicate localization of peripheral
myonuclei in wild-type (WT), central nuclei in ANT1−/− (ANT1-) and peripheral in transduced
ANT1−/− animals (tANT1-). Broken arrow indicates endomysial inflammation in ANT1−/−
tissues (Bar scales: 10 μm). (d) Reversal of hyperinduction of mitochondrial OXPHOS
enzymes by AAV-ANT1 transduction. Immunohistochemical stain for ANT1 and
histochemical stains for NADH-DH, SDH and COX of transverse-sectioned gastrocnemius
muscle of 3-month-old wild-type (WT), ANT1−/− (ANT1-) and ANT1−/− mice injected with
AAV-ANT1 as neonates (tANT1-) (bar scale: 50 μm).
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